LEXINGTON, Mass.

马萨诸州列克星敦

,

，

Aug. 13, 2026

2026年8月13日

/PRNewswire/ -- Curis, Inc. (Nasdaq:

/PRNewswire/ -- Curis, Inc.（纳斯达克：

CRIS

CRIS

), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of $1.50 per share and accompanying common warrant (or a combined public offering price of $1.49 per pre-funded warrant and accompanying common warrant) (the 'Offering').

），一家专注于开发emavusertib（CA-4948）的生物技术公司，今日宣布其公开发行的定价结果。本次发行面向某些新的及现有的专注于医疗保健领域的机构投资者，涉及购买和出售3,733,334股公司普通股（或用于替代普通股的预融资认股权证），以及最多可购买3,733,334股普通股的认股权证。每股普通股及附随普通认股权证的合并公开发行价格为1.50美元（或每份预融资认股权证及附随普通认股权证的合并公开发行价格为1.49美元）（以下简称“本次发行”）。

The common warrants will have an exercise price of $1.75 per share, will be exercisable immediately and will expire five years from the issuance date. The pre-funded warrants will have an exercise price of $0.01 per share and will be exercisable immediately until exercised in full..

普通权证的行权价格为每股1.75美元，可立即行权，并自发行之日起五年后到期。预融资权证的行权价格为每股0.01美元，可立即行权，直至全部行权完毕。

The gross proceeds from the Offering are expected to be approximately $5.6 million, before deducting placement agents fees and estimated Offering expenses payable by Curis. The Company intends to use the net proceeds of this Offering to fund its research and development activities and for working capital and general corporate purposes The Offering is expected to close on or about August 14, 2026, subject to market conditions and the satisfaction of customary closing conditions..

本次发行的总收益预计约为560万美元，未扣除配售代理费用及由Curis支付的预计发行费用。公司拟将本次发行的净收益用于资助其研发活动，以及用于营运资金和一般公司用途。预计本次发行将于2026年8月14日或前后完成，具体取决于市场状况及惯例交割条件的满足情况。

A.G.P./Alliance Global Partners is acting as the lead placement agent and Laidlaw & Company (UK) Ltd. is acting as co-placement agent in connection with the Offering.

A.G.P./Alliance Global Partners 担任本次发行的牵头配售代理，Laidlaw & Company (UK) Ltd. 担任联合配售代理。

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-298203) filed on August 10, 2026 and declared effective by the Securities and Exchange Commission (the 'SEC') on August 12, 2026. The Offering is being made only by means of a prospectus forming part of the effective registration statement.

上述证券正依据于2026年8月10日提交、并于2026年8月12日由美国证券交易委员会（“SEC”）宣布生效的S-1表格注册声明（文件编号：333-298203）进行发行。本次发售仅通过构成该生效注册声明一部分的招股说明书进行。

A preliminary prospectus related to the offering was filed with the SEC on August 10, 2026. The final prospectus related to the offering will be filed with the SEC and will be available on the SEC's website at .

与本次发行相关的初步招股说明书已于2026年8月10日向美国证券交易委员会（SEC）提交。与本次发行相关的最终招股说明书将向美国证券交易委员会提交，并可在美国证券交易委员会网站获取。

www.sec.gov

www.sec.gov

. Copies of the final prospectus relating to the offering, when available, may be obtained from: A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at

. 与本次发行相关的最终招股说明书副本在可获得时，可通过以下方式获取：A.G.P./Alliance Global Partners，地址：纽约州纽约市麦迪逊大道590号28层，邮编10022；电话：(212) 624-2060；电子邮件：

[email protected]

[email protected]

. The final terms of the offering will be disclosed in a final prospectus to be filed with the SEC.

发行的最终条款将在向美国证券交易委员会（SEC）提交的最终招股说明书中披露。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售任何所述证券的要约，也不构成购买任何所述证券的要约之招揽；在任何州或司法管辖区，若在根据该州或司法管辖区的证券法进行注册或资格认定之前，此类要约、招揽或销售属于违法行为，则不得在该州或司法管辖区销售这些证券。

About Curis, Inc.

关于 Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL).

Curis 是一家生物技术公司，专注于开发 emavusertib，这是一种可口服的小分子 IRAK4 和 FLT3 抑制剂。Emavusertib 目前正在两项临床试验中进行评估：一是在复发/难治性原发性中枢神经系统淋巴瘤（PCNSL）患者中，将 emavusertib 与 BTK 抑制剂伊布替尼联合使用的 TakeAim Lymphoma 1/2 期研究（CA-4948-101）；二是在慢性淋巴细胞白血病（CLL）患者中，将 emavusertib 与 BTK 抑制剂泽布替尼联合使用的 TakeAim CLL 2 期研究（CA-4948-203）。

The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL.

公司在急性髓系白血病（AML）领域的单药治疗和联合治疗研究已基本完成，公司计划通过额外资金继续推进emavusertib在AML中的开发。Emavusertib已获得美国食品药品监督管理局（FDA）授予的孤儿药资格，用于治疗原发性中枢神经系统淋巴瘤（PCNSL）、急性髓系白血病（AML）和骨髓增生异常综合征（MDS），并已获得欧盟委员会授予的孤儿药资格，用于治疗PCNSL。

Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948)..

Curis通过其2015年与Aurigene Discovery Technologies Limited的合作，拥有emavusertib（CA-4948）的独家许可。

Cautionary Note Regarding Forward-Looking Statements:

关于前瞻性陈述的警示说明：

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws, including without limitation, statements regarding the timing of the completion, and anticipated gross proceeds, of the offering, the use of proceeds for the offering and the terms of the common warrants and pre-funded warrants.

本新闻稿包含根据1995年美国《私人证券诉讼改革法》及其他联邦证券法律定义的前瞻性陈述，包括但不限于关于本次发行完成时间、预期募集资金总额、募集资金用途以及普通股认股权证和预付资金认股权证条款的陈述。

Forward-looking statements may contain the words 'believes,' 'expects,' 'anticipates,' 'plans,' 'intends,' 'seeks,' 'estimates,' 'assumes,' 'predicts,' 'projects,' 'targets,' 'will,' 'may,' 'would,' 'could,' 'should,' 'likelihood', 'continue,' 'potential,' 'opportunity,' 'focus,' 'strategy,' 'mission,' or similar expressions.

前瞻性陈述可能包含“相信”、“预期”、“预计”、“计划”、“打算”、“寻求”、“估计”、“假设”、“预测”、“规划”、“目标”、“将”、“可能”、“会”、“能够”、“应该”、“可能性”、“继续”、“潜力”、“机会”、“关注”、“战略”、“使命”或类似表述。

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions 'Risk Factor Summary' and 'Risk Factors' in our most recent Annual Report on Form 10-K and the factors that are discussed in other filings that Curis periodically makes with the SEC.

本新闻稿中包含的明示或暗示的前瞻性陈述仅为预测，并受多种风险、不确定性和假设的影响。可能导致实际结果与前瞻性陈述所指示的结果存在重大差异的其他重要因素，包括我们最新的10-K表格年度报告中“风险因素摘要”和“风险因素”标题下列出的因素，以及Curis定期向美国证券交易委员会（SEC）提交的其他文件中讨论的因素。

In addition, any forward-looking statements represent the views of Curis only as of the date of this press release and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law..

此外，任何前瞻性陈述仅反映Curis在本新闻稿发布之日的观点，不应被视为代表Curis在任何后续日期的观点。除非法律另有要求，Curis不承担任何因新信息、未来事件或其他原因而在本新闻稿发布之日后更新任何前瞻性陈述的意图或义务。

SOURCE Curis, Inc.

来源：Curis, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示